Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

CONCLUSIONSThe combination of ibrutinib and venetoclax was well tolerated in patients with relapsed or refractory CLL. Every patient responded and there was a high rate of MRD eradication, in some cases leading to the cessation of therapy.FigureDisclosuresHillmen: Pharmacyclics: Research Funding; Gilead Sciences, Inc.: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Alexion Pharmaceuticals, Inc: Consultancy, Honoraria; Acerta: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Celgene: Research Funding; Novartis: Research Funding. Rawstron: Pharmacyclics: Consultancy, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Beckman Coulter: Research Funding; BD Biosciences: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding. Brock: GlaxoSmithKline: Equity Ownership; AstraZeneca: Equity Owner...

Source: Blood - November 21, 2018 Category: Hematology Authors: Hillmen, P., Rawstron, A., Brock, K., Munoz Vicente, S., Yates, F., Bishop, R., Macdonald, D., Fegan, C., McCaig, A., Schuh, A., Pettitt, A., Gribben, J. G., Patten, P. E. M., Devereux, S., Bloor, A., Fox, C. P., Forconi, F., Munir, T. Tags: 642. CLL: Therapy, excluding Transplantation: Measurable Residual Disease in CLL: Moving Towards a Cure Source Type: research